Description
Sacituzumab is a humanized IgG1 monoclonal antibody targeting Trophoblast cell surface antigen 2 (TROP2). Sacituzumab demonstrates a lack of antitumor effects alone and does not inhibit the function of TROP-2 during tumor metastasis, binding to the linear epitopes of TROP-2 protein. Sacituzumab is used for the synthesis of antibody-drug conjugates (ADC) drugs. Antibody-drug conjugates with sacituzumab (sacituzumab govitecan) (HY-132254) targeting TROP-2 have been approved for the field of triple-negative breast cancer.
Cat.No
A620
Name
Sacituzumab
Chemical Properties
CAS
1796566-95-4
Synonyms
Sacituzumab;CYSTEINYL CL2A-SN-38;CYSTEINYL CL2A-SN-38;M9BYU8XDQ6;M9BYU8XDQ6;sacituzumab-govitecan;sacituzumab-govitecan;DTXSID401335985;DTXSID401335985;DTXSID401335985;hRS7-SN38;hRS7-SN38;hRS7-SN38;hRS7-SN38;IMMU 132;IMMU 132;IMMU 132;IMMU 132;SN-38 CYSTEINYL CONJUGATE;SN-38 CYSTEINYL CONJUGATE;SN-38 CYSTEINYL CONJUGATE;SN-38 CYSTEINYL CONJUGATE;IMMU-132;IMMU-132;IMMU-132;IMMU-132;Sacituzumab govitecan [USAN];Sacituzumab govitecan [USAN];Sacituzumab govitecan [USAN];Sacituzumab govitecan [USAN];EX-A4354;EX-A4354;EX-A4354;EX-A4354;DA64T2C2IO;DA64T2C2IO;DA64T2C2IO;DA64T2C2IO;1535963-91-7;1535963-91-7;1535963-91-7;1535963-91-7;DA-77702;DA-77702;DA-77702;DA-77702;GOVITECAN CYSTEINYL CONJUGATE;GOVITECAN CYSTEINYL CONJUGATE;GOVITECAN CYSTEINYL CONJUGATE;GOVITECAN CYSTEINYL CONJUGATE;F82944;F82944;F82944;F82944;Sacituzumab govitecan;Sacituzumab govitecan;Sacituzumab govitecan;Sacituzumab govitecan;hRS 7SN38;hRS 7SN38;hRS 7SN38;hRS 7SN38;Satralizumab linker;Satralizumab linker;Satralizumab linker;Satralizumab linker;1796566-95-4;1796566-95-4;1796566-95-4;1796566-95-4;UNII-M9BYU8XDQ6;UNII-M9BYU8XDQ6;UNII-M9BYU8XDQ6;UNII-M9BYU8XDQ6;1491917-83-9;1491917-83-9;1491917-83-9;1491917-83-9
pH value
Corresponds to reference standard: PASS
Non-reduced CE-SDS
>95%
SEC-HPLC
>95%
Isoelectric Point
Corresponds to reference standard
Bacterial Endotoxins Test
Residual Proteins of Host Cell
Exogenous Residual DNA
Residual protein A
Biological Activity
Osmolality
Corresponds to reference standard: PASS
Peptide mapping
Corresponds to reference standard: PASS
N-terminal sequence
Corresponds to reference standard: PASS
References
Return Policy
If you are in any way unsatisfied with your purchase, you may return any item(s) within 365 days of its original purchase date.
Please provide your Order Number in the email. We strive to reply to all email inquiries within one business day.
Tel: +86-21-58447131
Fax: +86-21-61642470
Email:
sales@dcchemicals.com
order@dcchemicals.com
Website:
www.dcchemicals.com